A case of new-onset psoriasis following durvalumab treatment in a patient with non-small cell lung cancer

Psoriasis is a chronic inflammatory skin disease in which the Th17 cell lineages play a crucial role in its pathogenesis.Durvalumab is an immune checkpoint inhibitors (ICIs) that blocks PD-L1 (programmed death-ligand 1) and has been approved for the treatment of various advanced and metastatic cancers.During administration of ICIs, excessive T-cell activation may lead to a range of immune-related adverse events, including cutaneous reactions.A 74-year-old man with no previous dermatologic history was diagnosed with non-small cell lung cancer and received durvalumab as consolidation therapy.About one month after initiation of durvalumab, erythematous scaly papules and plaques appeared on trunk.A skin biopsy confirmed the diagnosis of psoriasis.After treatment with topical corticosteroids and vitamin D analogue, the skin lesions improved, and durvalumab therapy was continued with close follow-up.Herein, we report a case of new-onset psoriasis following durvalumab treatment in a patient with non-small cell lung cancer.